Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.

摘要: To investigate the relationship between improved stability of an anticancer drug–lipiodol emulsion and pharmacokinetic (PK) profile for transarterial chemoembolisation (TACE) hepatocellular carcinoma (HCC). The four doxorubicin– or idarubicin–lipiodol emulsions was evaluated over 7 days. PK clinical data were recorded after TACE with most stable in eight unresectable HCC patients, institutional review board approval. one that combined idarubicin lipiodol (1:2 v:v). At 7 days, percentages aqueous, persisting oily phases 50-0-50, 33-0-67, 31-39-30, 10-90-0 doxorubicin–lipiodol (1:1 v:v), v:v) emulsion, respectively. After TACE, mean Cmax AUC0-24h 12.5 ± 9.4 ng/mL 52 ± 16 ng/mL*h. Within 24 h injection, 40 % liver, either vessels, tumours, hepatocytes. During 2 months no grade >3 adverse events occurred. One complete response, five partial responses, stabilisation, progression observed at 2 months. This study showed a promising favourable safety TACE. • Transarterial regimens improve survival are needed. Improved resulted profile. Preliminary efficacy encouraging.